Cytokinetics (CYTK) Q3 2024 earnings summary

Executive summary

• Completed rolling NDA submission for aficamten for obstructive HCM in the US and China, with priority review requested; commercial launch preparations underway in the US and Europe.

• Presented and published extensive new data from SEQUOIA-HCM and FOREST-HCM, reinforcing aficamten's safety and efficacy profile.

• Advanced late-stage pipeline: omecamtiv mecarbil (COMET-HF, Phase III) and CK-586 (AMBER-HFpEF, Phase II) trials to begin in Q4 2024; initiated IND-enabling work for CK-089.

• Entered significant financing agreements in 2024, including $200M from Royalty Pharma and a $563M public equity offering.

• Strengthened executive team and continued prudent capital deployment to support growth and pipeline expansion.

Financial highlights

• Ended Q3 2024 with $1.3 billion in cash, cash equivalents, and investments, down from $1.4 billion in Q2, but up from $655 million at year-end 2023 due to financing activities.

• Q3 2024 revenues were $0.5 million, up from $0.4 million year-over-year; nine-month revenues were $1.5 million, down from $5.9 million year-over-year.

• R&D expenses rose to $84.6 million (including $11.4 million stock-based comp), up from $82.5 million year-over-year.

• G&A expenses increased to $56.7 million (including $13.9 million stock-based comp), up from $40.1 million year-over-year, driven by commercial readiness investments.

• Net loss for Q3 2024 was $160.5 million ($1.36/share), compared to $129.4 million ($1.35/share) in Q3 2023; nine-month net loss was $439.5 million ($4.00/share).

Outlook and guidance

• Reiterated all aspects of prior 2024 financial guidance, including GAAP operating expense guidance of $555–$575 million and non-GAAP $445–$470 million.

• Preparing for potential US launch of aficamten in 2025, pending FDA approval; MAA submission to EMA planned for Q4 2024.

• Coordinating with Corxel for planned China launch of aficamten in 2025.

• Expecting MAPLE-HCM results in H1 2025; ACACIA-HCM and CEDAR-HCM enrollment ongoing, with completion targeted for 2025.

• COMET-HF (omecamtiv mecarbil, Phase III) and AMBER-HFpEF (CK-586, Phase II) trials to start in Q4 2024; CK-089 Phase 1 to start in Q4 2024.